Franck Lescure

Advisor Fundraising & Development Strategy / Life Sciences

Find him on :

Specialization

Venture Capital, Investor Readiness, Early-stage Development / Life Sciences & Deep Tech

Franck bridges scientific innovation and investment strategy. With more than 20 years of venture capital experience, complemented by a decade in technology innovation, he brings a deep understanding of how investors assess life sciences businesses—and what it takes to support their development.

At Vim Vitae, his proposed contribution is to help companies connect their financing ambitions with a credible growth strategy: translating scientific differentiation into an investment proposition, preparing for investor scrutiny and aligning funding milestones with commercial execution.

His experience includes :

Scientific and industrial experience at Genset and Air Liquide, preceding his transition into venture capital in 2002.

Investment roles at Crédit Lyonnais Private Equity, Auriga Partners, and Elaia Partners, with leadership of Auriga’s and Elaia’s life sciences franchises.

Experience in building investment teams, raising and developing funds, and as leading investor in several VC funds totalizing more than €400m AUM.

A scientific and business education spanning École Normale Supérieure, the Pasteur Institute, a PhD in Virology, and a MBA from the Collège des Ingénieurs.

Key expertise areas

Fundraising strategy and financing roadmaps

Investor readiness and investment positioning

Investor targeting and engagement preparation

Support in negotiation related to fundraising processes

Scientific and commercial investment narratives

Due diligence preparation

Alignment of financing, development and commercial milestones

Board-level advice and strategic growth planning

Notable engagements

Elaia Partners — Led life sciences development as Partner from 2018 to 2023, building an expert team and developing investment activities in life sciences and digital life sciences.

Auriga Partners — Served as Life Sciences Partner from 2004 to 2018, contributing to investment funds, including the fundraising and management of a seed investment fund.

ZINCC — Cumulated 30 advisor missions between 2023 and present, supporting startups, managing companies and public or private institutions, adressing technology innovation in healthcare, industrial biotechnologies or digital lifes sciences.

Investment track record — His biography lists investments in startups from his direct involvement or his team that subsequently achieved IPOs or acquisitions, among which Median Technologies IPO in 2011, Erytech Pharma IPO in 2013, Amoeba IPO in 2015, Mablink’s acquisition by Eli Lilly in 2023, or subsequently marketed products through regulatory process like Fabentech in 2025 or Phagenix in 2025 and 2026.

Markets

France and Europe, with a focus on biotechnology, healthcare, digital health and life sciences deep tech. His public biography documents investment experience across the French and European life sciences ecosystem.